# Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

> **NCT07011342** · NA · RECRUITING · sponsor: **Hackensack Meridian Health** · enrollment: 70 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 18F-rhPSMA-7.3

## Key facts

- **NCT ID:** NCT07011342
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07011342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07011342, "Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07011342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*